NICE

Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.

[NICE @NICEComms]

We've published our 2025 to 2026 annual report, spotlighting our key achievements and highlights: https://t.co/U7CVgj8L7r

Read to find out how we're delivering against the 10 Year Health Plan, and how we're becoming more relevant, timely, impactful and usable.

[NICE @NICEComms]

A groundbreaking approach to monitoring heart failure patients remotely has reduced unnecessary hospital admissions by 58%, improving patient experience and saving the NHS £4,158 per patient: https://t.co/JrIrLjxLGs

Developing or adopting healthtech? https://t.co/VPXEPKcT64

[NICE @NICEComms]

727 livers donated. Only 309 transplanted. More than half went unused last year.

New NICE draft guidance recommends a procedure that could enable around 150 more liver transplants every year, giving more people on the waiting list a fair chance:
https://t.co/vpxgczGkv8

@NHSBT

[NICE @NICEComms]

Around 1 in 10 NHS patients are alcohol dependent.

James knew this reality first-hand and used his experience to help more people get the right support.

Learn how James, a NICE lay committee member helped shape national guidance: https://t.co/UFtcvM9abd
#AlcoholAwarenessWeek

[NICE @NICEComms]

In the UK, average diagnosis takes over 9 years.

Endosure and Endotest can now be used in the NHS while more evidence is gathered.

Learn more: https://t.co/s2e5nnqcZW

👉Developing or adopting healthtech? Explore support: https://t.co/v2WeiJQqJU

[NICE @NICEComms]

It's 1 year since the announcement of the #10YearHealthPlan to transform the NHS. NICE is at the heart of delivering better, faster care for patients.
We're streamlining medicine access, accelerating approvals by 3-6 months, and ensuring innovations reach patients faster.

[NICE @NICEComms]

📅Join our NICE Advice seminar (21 July) to strengthen your NICE submission strategy.

Learn about real-world data & AI, health inequalities & presenting surrogate outcomes.

Develop stronger evidence with expert support.

Register here: https://t.co/Pkc8nwI37S

[NICE @NICEComms]

The technology is ready. Is the NHS?
https://t.co/qPxSn0JwCk

NICE CEO, Jonathan Benger explores what it will take to unlock the full potential of healthtech for NHS patients and how the new National Healthtech Access Programme is helping to make that happen.

@thenhenews

[NICE @NICEComms]

Stories like Sharon's are why this guideline matters.

Our new draft guidance on polyendocrine metabolic ovarian syndrome (PMOS) aims to improve diagnosis and long-term care for the 1 in 8 women affected.

Read the guideline and share your views by 11 Aug: https://t.co/OPcQyQDbCN

[NICE @NICEComms]

Polyendocrine metabolic ovarian syndrome (previously known as polycystic ovary syndrome) affects around 1 in 8 women in the UK, yet it's frequently under-diagnosed.

Our new draft guideline recommends annual reviews and aims to improve early diagnosis: https://t.co/WXmV0tevAo

[NICE @NICEComms]

“It’s difficult to put into words how grateful I am for this technology. It’s given me peace of mind and helped keep me out of hospital.”

Recommended by NICE, learn how this heart failure monitor helps people like Leslie manage their condition from home: https://t.co/2b1HRBqQDH

[NICE @NICEComms]

Up to 46,000 people living with acute migraine could soon access a new treatment on the NHS.

NICE has recommended atogepant in final guidance: https://t.co/RGrdfahIvT

[NICE @NICEComms]

We want to hear your views on a proposed update to our guideline that recommends clinicians consider the use of procalcitonin testing for some people with suspected severe sepsis. The consultation closes on July 10.

Find out how to take part: https://t.co/foonrC2g8O

[NICE @NICEComms]

Thousands of people with an autoimmune condition that leads to extensive hair loss are set to benefit after we recommended a new daily pill treatment today.

Find out more about deuruxolitinib: https://t.co/u3DsgbG7tL

[NICE @NICEComms]

Getting the right healthtech to patients faster matters.

Our chief executive spoke to the Science and Technology Select Committee yesterday on our work to establish a structured pathway from evidence to adoption.

👉Developing or adopting healthtech https://t.co/MXnZBqfoHh

[NICE @NICEComms]

"NICE's healthtech guidance provided me with the perfect catalyst for change."

With 187 slide sheet products on the market, how do you choose?

Evelyn Otunbade shares how our guidance helped balance quality and cost.

Read Evelyn's story: https://t.co/pq2uM1T0b9

@NHSSupplyChain

[NICE @NICEComms]

NICE has recommended a new first-line NHS treatment for locally advanced cervical cancer.

Pembrolizumab with chemoradiotherapy has the potential to improve survival and increase the chance of cure for people: https://t.co/ZG3H45E22O

[Breakthrough T1D UK @BT1DUK]

"The greatest gift teplizumab has given us is time. As a mother, every month and every year that Dima can continue being a child without insulin injections, carb counting and the daily burden of T1D feels incredibly precious."

Elena's son Dima was nine when he received a positive result for early onset type 1 diabetes (T1D). This was followed by a call from @elsadiabetes about a new immunotherapy called teplizumab that could change everything. After careful consideration and talking to her sister, whose daughter was also diagnosed at seven years old, Elena agreed to taking part in the treatment, "if there was a chance we could delay the need for insulin, I thought it was worth it."

The treatment lasted two weeks, delivered once a day via infusion followed by a few hours of monitoring. After the treatment, Dima returned home and resumed normal life. So far, he remains symptom-free.

Stories like this one is why we do what we do - so people like Elena and her son Dima have more time. Time for childhood to still feel like childhood. Time for parents to adapt to supporting a life-changing and lifelong condition. None of this would be possible without you, our incredible community. 💙

This is only the beginning. We won't stop until we find a cure.

You can read Elena's full story here: https://t.co/ByNoA5q0AT

#GBDoc #Type1Diabetes #Teplizumab

[NICE @NICEComms]

We've published final guidance recommending seladelpar for people living with primary biliary cholangitis, a rare liver disease where the immune system attacks the bile ducts, which can lead to liver failure.

Around 3,700 people could benefit: https://t.co/EtXqbecb9D

[NICE @NICEComms]

Elena signed her 9-year-old son Dima up to a screening study and found out he had early-stage type 1 diabetes.

He received teplizumab, a new treatment now recommended for NHS use that can delay onset by nearly 3 years.

Read more: https://t.co/wy4i7WEE9V